1083 related articles for article (PubMed ID: 29342367)
1. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
2. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
3. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
4. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
5. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
Habib AR; Kajbafzadeh M; Desai S; Yang CL; Skolnik K; Quon BS
Sci Rep; 2019 May; 9(1):7234. PubMed ID: 31076617
[TBL] [Abstract][Full Text] [Related]
8. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
Sagel SD; Khan U; Heltshe SL; Clancy JP; Borowitz D; Gelfond D; Donaldson SH; Moran A; Ratjen F; VanDalfsen JM; Rowe SM
Ann Am Thorac Soc; 2021 Jan; 18(1):75-83. PubMed ID: 32644818
[No Abstract] [Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.
Kim C; Higgins M; Liu L; Volkova N; Zolin A; Naehrlich L;
J Cyst Fibros; 2024 May; 23(3):436-442. PubMed ID: 38402082
[TBL] [Abstract][Full Text] [Related]
13. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
14. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
[TBL] [Abstract][Full Text] [Related]
16. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
Berkers G; van der Meer R; Heijerman H; Beekman JM; Boj SF; Vries RGJ; van Mourik P; Doyle JR; Audhya P; Yuan ZJ; Kinnman N; van der Ent CK
J Cyst Fibros; 2021 Sep; 20(5):761-767. PubMed ID: 33249003
[TBL] [Abstract][Full Text] [Related]
17. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
[TBL] [Abstract][Full Text] [Related]
18. Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction.
Wark PAB; Cookson K; Thiruchelvam T; Brannan J; Dorahy DJ
BMC Pulm Med; 2019 Jun; 19(1):106. PubMed ID: 31208380
[TBL] [Abstract][Full Text] [Related]
19. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
[TBL] [Abstract][Full Text] [Related]
20. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
